UCB Expands Bimzelx Indications with Three New FDA Approvals for Chronic Inflammatory Diseases

Bimzelx, UCB, FDA approvals, psoriatic arthritis, non-radiographic axial spondyloarthritis, ankylosing spondylitis, IL-17A, IL-17F inhibitor

FDA Approves Bimzelx for Expanded Indications: Psoriatic Arthritis, Non-Radiographic Axial Spondyloarthritis, and Ankylosing Spondylitis

Bimzelx, FDA approval, psoriatic arthritis, non-radiographic axial spondyloarthritis, ankylosing spondylitis, IL-17A and IL-17F inhibitor